氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描对接受新辅助化疗的激素受体阳性、HER2 阴性乳腺癌患者预测病理完全缓解的效用。
Utility of F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy.
机构信息
Department of Oncology/Hematology, Catholic University of Daegu, School of medicine, Daegu, South Korea.
Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, Kyungpook National University, Daegu, South Korea.
出版信息
BMC Cancer. 2020 Nov 16;20(1):1106. doi: 10.1186/s12885-020-07505-w.
BACKGROUND
Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative breast cancer, the response to NAC is variable and mostly limited. This study was an investigation of the predictive relevance of parameters of F-FDG PET/CT for the pCR to NAC in patients with HR-positive, HER2-negative breast cancer.
METHODS
AH total of 109 consecutive HR-positive and HER2-negative breast cancer patients who were treated with NAC were enrolled in this prospective cohort study. The relationships between pretreatment F-FDG PET/CT and clinical outcomes including pathologic response to NAC were evaluated.
RESULTS
All patients finished their planned NAC cycles and eight patients (7.3%) achieved pCR. In the receiver operating characteristic (ROC) curve analysis, pSUVmax exhibited high sensitivity and specificity for predicting pCR. Furthermore, multivariate logistic regression analysis revealed pSUVmax as a predictive factor for pCR (hazard ratio = 17.452; 95% CI = 1.847-164.892; p = 0.013).
CONCLUSION
The results of this study suggest that F-FDG PET/CT pSUVmax is a predictive factor for pCR of HR-positive, HER2-negative breast cancer to NAC.
背景
新辅助化疗（NAC）后病理完全缓解（pCR）是乳腺癌患者预后改善的预测指标。在激素受体（HR）阳性、人表皮生长因子受体 2（HER2）阴性的乳腺癌患者中，NAC 的反应是可变的，且大多有限。本研究旨在探讨 F-FDG PET/CT 参数对 HR 阳性、HER2 阴性乳腺癌患者 NAC 后 pCR 的预测价值。
方法
本前瞻性队列研究共纳入 109 例接受 NAC 治疗的 HR 阳性、HER2 阴性乳腺癌患者。评估了治疗前 F-FDG PET/CT 与包括 NAC 病理反应在内的临床结局之间的关系。
结果
所有患者均完成了计划的 NAC 周期，8 例（7.3%）患者达到 pCR。在受试者工作特征（ROC）曲线分析中，pSUVmax 对预测 pCR 具有较高的敏感性和特异性。此外，多变量逻辑回归分析显示，pSUVmax 是 pCR 的预测因素（危险比=17.452；95%置信区间=1.847-164.892；p=0.013）。
结论
本研究结果表明，F-FDG PET/CT 的 pSUVmax 是 HR 阳性、HER2 阴性乳腺癌对 NAC 后 pCR 的预测因素。
Zotero 插件